Biocracked
Conceptual metaphor: a cube of pale yellow wax, the size of a fist, stands for abdominal fat. A clear glass syringe is inserted into its top face, and one small, smooth, glossy crater has melted around the needle. The rest of the cube stays sharp-edged and untouched, which shows the effect is local, not systemic. Fine droplets of melted wax bead at the crater's rim. The syringe plunger has a small electric green tip.

The camera is at a low three-quarter angle with a shallow depth of field, focused on the needle entry point. The cube sits on a seamless saturated teal backdrop and a matching glossy teal surface, with a faint reflection beneath it. Soft, directional studio light comes from the upper left, giving the wax a translucent glow and crisp highlights on the glass. Shadows are neutral grey-teal, not blue-black.

The mood is precise, curious and slightly skeptical, with a clean, modern, photorealistic look.
Research

Apa iku CBL‑514? Apa iki pembakar lemak?

Dr. Synapse · · 5 min read

CBL‑514 (kadhangkala salah diketik dadi "CL‑514") saiki kerep dibahas ing internet minangka suntikan sing nglarutaké lemak. Gambaran iki setengah bener, nanging istilah "pembakar lemak" ora tepat. CBL‑514 iku obat suntikan molekul cilik sing saiki diteliti kanggo lipolisis déning Caliway Biopharmaceuticals, New Taipei City, Taiwan. Obat iki didesain supaya nyebabaké apoptosis sel lemak ing wilayah sing disuntik. Dadi, iki dudu pembakar lemak metabolik, ora GLP‑1, lan ora suplemen.

Apa CBL‑514 iku, lan apa dudu

Jeneng sing bener yaiku CBL‑514. "CL‑514" mung typo sing kerep muncul ing sawetara artikel, lan iki siji‑sijine panggonan tembung kasebut muncul ing artikel iki.

CBL‑514 iku:

  • Suntikan molekul cilik sing isih diteliti.
  • Diparingi subkutan ing wilayah sing ditangani, ing uji coba fase II wilayah iki lemak abdomen.
  • Diberi déning peneliti ing uji klinis.

CBL‑514 dudu:

  • Suplemen utawa pil oral.
  • Produk konsumen sing wis disetujui.
  • Wis disetujoni FDA (kanggone saiki isih tahap eksperimen).

Suntikan siji‑satune sing wis disetujoni FDA kanggo ngurangi lemak yaiku ATX‑101 (deoxycholic acid, dipasaraké kanthi jeneng Kybella). ATX‑101 mung disetujoni kanggo lemak submental (lemak ngisor dhadha). CBL‑514 lagi diteliti kanggo wilayah sing luwih gedhé, yaiku abdomen, nanging isih minangka senyawa eksperimental.

Mekanisme sing diusulaké

Makalah fase II nerangaké CBL‑514 minangka "agen lipolisis suntikan molekul cilik sing nambah apoptosis adiposit lan ngurangi lemak subkutan target ing studi nonklinis." Klaim nonklinis iki sebagian adhedhasar laporan rahasia Caliway sing ora dipublikasikaké lan makalah Phase 2a open‑label sing luwih cilik (Goodman et al., 2022). Miturut karya kuwi, CBL‑514 ngendhalèni kinase DYRK1b sing njaga sel lan nambah mediator apoptosis caspase 3 lan Bax/Bcl‑2. Iki dilaporaké ngasilaké apoptosis adiposit kanthi dosis ing vitro lan in vivo. Ringkesané, gagasané yaiku nyurung sel lemak ing zona sing disuntik supaya mlebu proses mati sel sing diprogram, ora kanggo ningkataké metabolisme utawa ngobur kalori sakabèhé.

Struktur kimia molekul iki ora diumumaké ing makalah, mula klaim apa‑apa bab identitas persis, reseptor, utawa bahan aktif mung spéculasi.

Bukti manungsa: uji coba fase II taun 2025

Data utama asalé saka uji coba acak, single‑blind, kontrol placebo fase II. Uji iki dilakokaké ing lima pusat ing AS lan Australia saka Februari 2022 nganti Maret 2023 lan dipublikasikaké ing Aesthetic Surgery Journal taun 2025 (level bukti 2).

  • Ukuran sampel: 130 disaring, 81 mlebu, 76 dirandomisasi (50 CBL‑514, 26 placebo), 75 ditambani.
  • Peserta: wong diwasa umur 18‑64 taun kanthi BMI > 18,5 lan < 35 kg/m². Ing grup CBL‑514, 94 % yaiku wanita.
  • Dosis: nganti patang perawatan kanthi jarak 4 minggu. Saben perawatan nggunakake 25‑50 suntikan (2,4 mL) kanthi konsentrasi 2 mg/cm², maksimal 600 mg saben perawatan. Placebo yaiku larutan garam fisiologis.
  • Pengukuran: ketebalan lemak ultrasound ing patang titik, diubah dadi volume ing area perawatan 300 cm².

Blinding dadi watesan. Mung peserta sing diblind, déné peneliti, staf situs, lan sponsor ora diblind. Caliway uga melu desain studi, analisis data lan interpretasi, nulis manuskrip, lan keputusan publikasi.

Dadi, apa iki pembakar lemak?

Obat iki ngurangi volume lemak lokal dibandhingake placebo. Ora ndadékaké pembakaran lemak sistemik utawa penurunan bobot.

Ing lemak lokal, studi iki nyukupi target utama yaiku setidaknya 150 mL penurunan volume lemak. Ing analisis intention‑to‑treat (ITT):

  • 4 minggu sawisé perawatan pungkasan: 63,9 % peserta CBL‑514 (23/36) nggayuh paling ora 150 mL, dibandhingake 17,4 % placebo (4/23), P < .001.
  • 8 minggu: 69,6 % (16/23) vs 0,0 % (0/16), P < .001.
  • Rata‑rata penurunan: beda rata‑rata paling‑kecil (least‑squares) dibanding placebo yaiku ‑206,62 mL ing 4 minggu lan ‑216,28 mL ing 8 minggu.
  • Penurunan tunggal paling gedhé: luwih saka 750 mL ing siji peserta.

Ing bobot awak, rata‑rata perubahan grup CBL‑514 yaiku +0,45 kg ing kontrol 4 minggu lan +0,02 kg ing 8 minggu. Grup placebo ngalami penurunan ‑0,76 kg lan ‑0,26 kg. Makalah ora nemokaké owah‑owahan signifikan ing rata‑rata bobot utawa BMI. Uga disebutaké sawetara peserta sing nambah > 1 kg nanging tetep nampilaké reduksi lemak lokal, sanajan data kuwi ora dipasrahaké. Pola iki cocok karo pendekatan sing ngresiki sel lemak lokal, ora kaya pembakar lemak metabolik.

Peringatan sadurunge sampeyan kepengin nyoba

Angka‑angka iki nyenengaké kanggo uji coba awal, nanging makalah iki duwé watesan nyata.

  • Drop‑out dhuwur. Saka 75 peserta sing ditambani, 38 ngrampungaké studi lan 37 ora, tingkat non‑completion 49,3 %. Alasan kalebu ilang kontak, penarikan diri, fluktuasi bobot, masalah jadwal, lan efek samping (4 peserta).
  • Denominator sing nyusut. Persentase ITT dhuwur adhedhasar 36 banjur 23 peserta CBL‑514 amarga follow‑up sing ilang.
  • Kelompok per‑protocol (PP) cilik. Populasi PP mung 30 wong. Efek luwih gedhé (rata‑rata ‑314,70 mL ing 4 minggu) asalé saka peserta sing tetep melu lan njaga bobot stabil, saéngga data iki luwih nguntungaké obat.
  • Desain eksploratori. Ukuran sampel ora adhedhasar perhitungan power formal, lan analisis ora diatur kanggo testing ganda.
  • Populasi sempit. Mayoritas peserta wanita lan mayoritas kulit putih.
  • Volume sing dihitung saka ultrasound. Volume dihitung nganggo rumus kuboid saka ketebalan ultrasound, ora diukur langsung.

Penulis uga mbandhingaké asil iki karo studi cryolipolysis lan nyatakake tren “kaya luwih gedhé,” lan nyebutaké asil iki padha karo liposuction. Iki interpretasi penulis. Metode pengukuran beda, lan ora ana uji coba head‑to‑head karo CoolSculpting utawa liposuction. Kesimpulan babagan kelenturan kulit adhedhasar gambar pasca‑perawatan, ora saka endpoint kelenturan formal.

Keamanan dinilai liwat efek samping, laboratorium, vitals, ECG, pemeriksaan fisik, lan reaksi ing situs suntikan. Pembaca sing peduli babagan tolerabilitas kudu maca bagian keamanan ing makalah lengkap tinimbang ngandelake ringkesan.

Ringkesan kanggo para biohacker

CBL‑514 minangka potongan biotek menarik: molekul cilik sing dimaksudaké supaya sel lemak ing wilayah sing ditambani ngalami apoptosis. Data fase II nuduhaké bisa ngurangi volume lemak abdomen luwih akeh tinimbang saline, kanthi perubahan bobot sing praktis ora ana. Iki karakteristik obat kontur tubuh sing ditarget, dudu pembakar lemak.

Obat iki uga isih eksperimental. Durung disetujoni, lan dudu suplemen. Ora disaranake kanggo dibeli utawa disuntik dhewe. Apa wae sing didol kanthi jeneng iki ing internet ing luar uji klinis iku ora jelas, lan struktur senyawa durung diumumaké. Uji coba sing luwih gedhé, luwih apik diblind, lan jangka panjang bakal kudu mènèhi bukti apa asil awal iki tahan.

Sumber: Gold M, Schlessinger J, Goodman GJ, et al. Efficacy and Safety of CBL‑514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single‑Blind, Placebo‑Controlled Phase II Study. Aesthetic Surgery Journal. 2025;45(6):611‑620. PMC12080885 | PMID 40037659 | doi.org/10.1093/asj/sjaf032

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
research

Injeksi Lipolisis CBL-514: Peta Bukti Fase II

BY DR. SYNAPSE ·

CBL-514 yaiku suntikan molekul cilik sing lagi diteliti supaya sel lemak (adiposit) ngalami apoptosis lan njalari pangurangan kantong lemak ing weteng. Ing uji fase II sing dilakokaké ing taun 2025 kanthi 76 peserta acak, volume lemak sing diukur nganggo ultrasound nyusut drastis dibandhingake karo saline, nanging bobot awak ora owah. Tulisan iki nerangake desain, dosis 2 mg/cm², data efektifitas lengkap karo denominator sing saya cilik, lan mekanisme DYRK1b‑caspase sing dilaporaké perusahaan. Nanging uga disorot watesan penting: desain siji‑blind, peran sponsor, attrisi 49 %, follow‑up sing cekak, lan mayoritas partisipan wanita.

Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
research

Dosis CBL‑514 – Apa sing Dikatakan Ilmu?

BY DR. SYNAPSE ·

Trial CBL‑514 iku protokol injeksi investigasional, lan angka “600 mg” iku wates maksimum saben perawatan, dudu dosis suplemen. Artikel iki nerangaké studi fase 2a sing nggolèki dosis (1,2, 1,6, lan 2,0 mg/cm² ing area 150 cm², n=43, open‑label) lan nerangaké asal‑usul angka 24,96 % sing asring disebut. Banjur dibahas fase 2 kanthi kontrol plasebo, sing tetep nganggo 2,0 mg/cm² nanging nambah area dadi 300 cm² lan wates dadi 600 mg. Sampeyan bakal ngerti kenapa total mg ora bisa dibandhingaké antarane studi, apa sing dilaporaké babagan keamanan, lan kenapa iki isih ora disetujui utawa dadi saran.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Apa CBL‑514 Tenan Ngobong Lemak? Kabeh Sing Kita Ngerti

BY HELIX WARD ·

Uji coba fase 2 CBL‑514 ing taun 2025 ora ngukur penurunan bobot awak, nanging nyoba apa suntikan langsung menyang jaringan lemak ing weteng bisa ngurangi paling ora 150 mL volume lemak subkutan sing diukur nganggo ultrasonik. Sawisé wolung minggu, 69,6 % (16 saka 23) partisipan sing nampa CBL‑514 nganti target iki, dene kelompok plasebo ora ana sing nggayuh. Nanging rata‑rata bobot awak malah ora mudhun (+0,02 kg), separo partisipan ora ngrampungake studi, lan jumlah partisipan sing netepi protokol mung 30 wong. Reaksi situs suntikan umum, kaya owah‑warna (71,4 %) lan rasa lara sing serius (18,4 %).

**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
research

Kepiye Cara Kerja CBL-514? Iki Ilmu Penjenengané

BY DR. SYNAPSE ·

CBL-514 ora dianggep minangka obat sing nglebur lemak. Klaimé ngganggu sinyal urip sel lemak lan nyurung sel kasebut mlebu proses apoptosis liwat DYRK1b, caspase‑3 lan Bax/Bcl‑2. Buktine asalé saka laporan perusahaan sing durung dipublikasikaké, dene struktur kimiane ora diwartakake. Uji fase 2 taun 2025 mung ngukur volume lemak nganggo ultrasonik lan foto, tanpa biopsi utawa data caspase. Artikel iki misahaké hipotesis molekuler saka apa sing saktenané diukur ing manungsa, kalebu tingkat dropout sing dhuwur lan rancangan single‑blind.

This page is available in